Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Nakashiro, S. Hara, Y. Shinohara, M. Oyasu, H. Kawamata, S. Shintani, H. Hamakawa, R. Oyasu (2004)
Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R.The American journal of pathology, 165 2
P. Ma, G. Maulik, J. Christensen, R. Salgia (2003)
c-Met: Structure, functions and potential for therapeutic inhibitionCancer and Metastasis Reviews, 22
T. Kosaka, Y. Yatabe, H. Endoh, Kimihide Yoshida, T. Hida, M. Tsuboi, H. Tada, H. Kuwano, T. Mitsudomi (2006)
Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to GefitinibClinical Cancer Research, 12
T. Shibata, S. Uryu, A. Kokubu, F. Hosoda, M. Ohki, T. Sakiyama, Y. Matsuno, R. Tsuchiya, Y. Kanai, T. Kondo, I. Imoto, J. Inazawa, S. Hirohashi (2005)
Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic FeaturesClinical Cancer Research, 11
W. Pao, Theresa Wang, Gregory Riely, V. Miller, Qiulu Pan, M. Ladanyi, M. Zakowski, R. Heelan, M. Kris, H. Varmus (2005)
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or ErlotinibPLoS Medicine, 2
D. Molyneux, P. Hotez, A. Fenwick (2005)
“Rapid-Impact Interventions”: How a Policy of Integrated Control for Africa's Neglected Tropical Diseases Could Benefit the PoorPLoS Medicine, 2
M. Janssen‐Heijnen, J. Coebergh (2001)
Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe.Lung cancer, 31 2-3
T. Goya, H. Asamura, H. Yoshimura, H. Kato, K. Shimokata, R. Tsuchiya, Y. Sohara, T. Miya, Etsuo Miyaoka (2005)
Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study.Lung cancer, 50 2
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
Y. Fukuyama, Tetsuya Mitsudomi, Kenji Sugio, Teruyoshi Ishida, Kouhei Akazawa, K. Sugimachi (1997)
K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer.British Journal of Cancer, 75
K. Sugio, H. Uramoto, K. Ono, T. Oyama, T. Hanagiri, M. Sugaya, Y. Ichiki, T. So, S. Nakata, Masaru Morita, K. Yasumoto (2006)
Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smokingBritish Journal of Cancer, 94
T. Kosaka, Y. Yatabe, Ryoichi Onozato, H. Kuwano, T. Mitsudomi (2009)
Prognostic Implication of EGFR, KRAS, and TP53 Gene Mutations in a Large Cohort of Japanese Patients with Surgically Treated Lung AdenocarcinomaJournal of Thoracic Oncology, 4
M. Beau-Faller, A. Ruppert, Anna Voegeli, A. Neuville, Nicolas Meyer, E. Guérin, M. Legrain, B. Mennecier, J. Wihlm, G. Massard, E. Quoix, P. Oudet, M. Gaub (2008)
MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naïve CohortJournal of Thoracic Oncology, 3
M. Shinohara, A. Kodama, T. Matozaki, A. Fukuhara, K. Tachibana, H. Nakanishi, Y. Takai (2001)
Roles of Cell-Cell Adhesion-dependent Tyrosine Phosphorylation of Gab-1*The Journal of Biological Chemistry, 276
W. You, D. McDonald (2008)
The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.BMB reports, 41 12
C. Mountain (1997)
Revisions in the International System for Staging Lung Cancer.Chest, 111 6
C. Huang, T. Taki, M. Adachi, T. Konishi, M. Higashiyama, M. Kinoshita, T. Hadama, M. Miyake (1998)
Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.International journal of oncology, 12 3
N. Cipriani, O. Abidoye, E. Vokes, R. Salgia (2009)
MET as a target for treatment of chest tumors.Lung cancer, 63 2
Ryoichi Onozato, T. Kosaka, H. Kuwano, Y. Sekido, Y. Yatabe, T. Mitsudomi (2009)
Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung CancersJournal of Thoracic Oncology, 4
M. Stella, L. Trusolino, Selma Pennacchietti, P. Comoglio (2005)
Negative Feedback Regulation of Met-Dependent Invasive Growth by NotchMolecular and Cellular Biology, 25
A. Guo, J. Villén, J. Kornhauser, Kimberly Lee, M. Stokes, Klarisa Rikova, A. Possemato, J. Nardone, Gregory Innocenti, R. Wetzel, Yi Wang, J. Macneill, Jeffrey Mitchell, S. Gygi, J. Rush, R. Polakiewicz, M. Comb (2008)
Signaling networks assembled by oncogenic EGFR and c-MetProceedings of the National Academy of Sciences, 105
Susumu Kobayashi, T. Boggon, Tajhal Dayaram, P. Jänne, O. Kocher, M. Meyerson, B. Johnson, M. Eck, D. Tenen, B. Halmos (2005)
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 352 8
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 350 21
H. Uramoto, K. Sugio, T. Oyama, K. Ono, M. Sugaya, T. Yoshimatsu, T. Hanagiri, M. Morita, K. Yasumoto (2006)
Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.Lung cancer, 51 1
Stephen Graziano, Gary Gamble, Nancy Newman, Lynn Abbott, Michelle Rooney, Sulagna Mookherjee, Melissa Lamb, L. Kohman, Bernard Poiesz (1999)
Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 17 2
E. Ichimura, Arafumi Maeshima, T. Nakajima, Toshikazu Nakamura (1996)
Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic SignificanceJapanese Journal of Cancer Research : Gann, 87
I. Takanami, Fumihiko Tanana, T. Hashizume, K. Kikuchi, Yasuki Yamamoto, Tatsuya Yamamoto, S. Kodaira (1996)
Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers.Oncology, 53 5
D. Allred, J. Harvey, M. Berardo, G. Clark (1998)
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 11 2
J. Eder, G. Woude, S. Boerner, P. LoRusso (2009)
Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in CancerClinical Cancer Research, 15
Yusuke Nakamura, T. Niki, A. Goto, Teppei Morikawa, K. Miyazawa, J. Nakajima, M. Fukayama (2007)
c‐Met activation in lung adenocarcinoma tissues: An immunohistochemical analysisCancer Science, 98
W. Pao, V. Miller, K. Politi, Gregory Riely, R. Somwar, M. Zakowski, M. Kris, H. Varmus (2005)
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLoS Medicine, 2
Stanley Zlotkin, Claudia Schauer, A. Christofides, W. Sharieff, M. Tondeur, S. Hyder (2005)
Micronutrient Sprinkles to Control Childhood AnaemiaPLoS Medicine, 2
(2001)
Japan: Ministry of Health, Labor and Welfare
J. Engelman, K. Zejnullahu, T. Mitsudomi, Youngchul Song, Courtney Hyland, Joon-Oh Park, N. Lindeman, Christopher-Michael Gale, Xiaojun Zhao, J. Christensen, T. Kosaka, A. Holmes, A. Rogers, F. Cappuzzo, T. Mok, Charles Lee, B. Johnson, L. Cantley, P. Jänne (2007)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 316
K. Okuda, H. Sasaki, H. Yukiue, M. Yano, Y. Fujii (2008)
Met gene copy number predicts the prognosis for completely resected non‐small cell lung cancerCancer Science, 99
Michael Huncharek, Joshua Muscat, J. Geschwind (1999)
K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases.Carcinogenesis, 20 8
S. Yano, Wei Wang, Qi Li, Kunio Matsumoto, Haruko Sakurama, Takahiro Nakamura, H. Ogino, S. Kakiuchi, M. Hanibuchi, Y. Nishioka, H. Uehara, T. Mitsudomi, Y. Yatabe, Toshikazu Nakamura, S. Sone (2008)
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.Cancer research, 68 22
W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, Bhuvanesh Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, Doris Kupfer, R. Wilson, M. Kris, H. Varmus (2004)
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.Proceedings of the National Academy of Sciences of the United States of America, 101 36
T. Onitsuka, H. Uramoto, N. Nose, M. Takenoyama, T. Hanagiri, K. Sugio, K. Yasumoto (2010)
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.Lung cancer, 68 2
J. Siegfried, L. Weissfeld, P. Singh-Kaw, R. Weyant, J. Testa, R. Landreneau, R. Landreneau (1997)
Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.Cancer research, 57 3
H. Uramoto, K. Sugio, T. Oyama, M. Sugaya, T. Hanagiri, K. Yasumoto (2006)
Resistance to gefitinibInternational Journal of Clinical Oncology, 11
ORIGINAL ARTICLE Comprehensive Molecular Analyses of Lung Adenocarcinoma with Regard to the Epidermal Growth Factor Receptor, K-ras, MET, and Hepatocyte Growth Factor Status Takamitsu Onitsuka, MD,* Hidetaka Uramoto, PhD, MD,* Kenji Ono, PhD, MD,* Mitsuhiro Takenoyama, PhD, MD,* Takeshi Hanagiri, PhD, MD,* Tsunehiro Oyama, PhD, MD,† Hiroto Izumi, PhD, MD,‡ Kimitoshi Kohno, PhD, MD,‡ and Kosei Yasumoto, PhD, MD* The wild type of K-ras, negative p-MET 1234/1235, and positive Background: The mutation and amplification of oncogenic genes expression of HGF may be a useful marker for predicting poor are associated with carcinogenesis and tumor growth. The purpose prognosis of patients who underwent surgical resection of lung of this study was to clarify the role of the epidermal growth factor adenocarcinoma. receptor (EGFR), K-ras, MET, and hepatocyte growth factor (HGF) Key Words: EGFR, K-ras, MET, HGF, Lung cancer, status in lung adenocarcinoma. Adenocarcinoma. Methods: Tumor specimens were collected from 183 patients who underwent a complete resection for adenocarcinoma of the lung (J Thorac Oncol. 2010;5: 591–596) from 2003 to 2007 in our department. The genetic status of the EGFR and K-ras genes were investigated by polymerase chain reaction (PCR)-based analyses. Immunohistochemistry and real time ung cancer is the leading cause
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: May 1, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.